Drugs / FACTOR X
FACTOR X
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT01721681 | Apr 2015 → Oct 2016 | factor X deficiency | Bio Products Laboratory | Completed | No outcome recorded |
| Phase 3 | NCT01086852 | Mar 2011 → Jan 2014 | factor X deficiency | Bio Products Laboratory | Terminated | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT00930176 | Jan 2010 → Nov 2013 | factor X deficiency | Bio Products Laboratory | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FACTOR X | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01086852 ↗ |
| Known as | Human Coagulation Factor X | “Human Coagulation Factor X” NCT01086852 ↗ |
| Known as | pdFX | “25 IU/kg plasma-derived factor X (pdFX) was administered as on-demand treatment or short-term prophylaxis for 6 months to 2 years.” PMID 29545231 ↗ Mar 2018 |
| Modality | Protein / enzyme biologic | “25 IU/kg plasma-derived factor X (pdFX) was administered as on-demand treatment or short-term prophylaxis for 6 months to 2 years.” PMID 29545231 ↗ Mar 2018 |
| Route | Intravenous | “Intravenous infusion of factor X is given at a suggested rate of 10mL/min but not exceeding more than 20mL/min.” NCT01086852 ↗ |